Drug Profile
Research programme: metabolic and musculoskeletal disorders therapeutics - Amylin/Xenome
Latest Information Update: 15 Nov 2013
Price :
$50
*
At a glance
- Originator Amylin Pharmaceuticals; Xenome
- Developer Amylin Pharmaceuticals
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Metabolic disorders; Musculoskeletal disorders
Most Recent Events
- 07 Nov 2013 Discontinued - Preclinical for Metabolic disorders in USA (Parenteral)
- 07 Nov 2013 Discontinued - Preclinical for Musculoskeletal disorders in USA (Parenteral)
- 08 Aug 2012 Amylin Pharmaceuticals has been acquired by Bristol-Myers Squibb